Related Experiment Videos
Noninvasive colorectal cancer screening.
Keshab D Pant1, John D McCracken
1Department of Gastroenterology, Loma Linda Medical Center, California 92350, USA.
Digestive Diseases and Sciences
|June 18, 2002
Summary
This study introduces a novel fecal test detecting abnormal mucin (COTA) for colorectal neoplasia screening. The COTA assay shows promise as a sensitive and specific method for identifying colon cancer and adenomas.
Area of Science:
- Oncology
- Gastroenterology
- Biochemistry
Background:
- Colorectal cancer cells produce abnormal mucin with the STn epitope, distinct from normal colonic mucin.
- Screening for colorectal neoplasia is crucial for early detection and improved patient outcomes.
Purpose of the Study:
- To develop and evaluate a technique for detecting abnormal mucin in fecal samples.
- To assess the efficacy of this novel assay as a screening method for colorectal neoplasia.
Main Methods:
- Soluble glycoproteins were isolated from fecal samples via centrifugation and ethanol precipitation.
- An immunoassay (slot dot) using anti-COTA monoclonal antibody SP-21 was employed to detect the STn epitope.
- Quantitative analysis of COTA was performed using an imaging densitometer and a standard curve.
Main Results:
- The COTA assay identified 5/6 colon cancers, 6/22 adenomas, 1/8 colitis cases, and 2/58 normal patients as positive.
- A threshold of >15 microg/ml COTA was established for positive neoplasia results.
- The pilot study indicated the COTA assay's sensitivity and specificity compared to Hemoccult screening.
Conclusions:
- The developed COTA assay is a promising tool for fecal-based screening of colorectal neoplasia.
- This method demonstrates potential for improved sensitivity and specificity over existing screening techniques.
- Further validation is warranted to establish the COTA assay's clinical utility in colorectal cancer screening.